Benzinga | Mar 17, 2021 07:10AM EDT

Lantern Pharma Announces Filing Of Seven Patent Applications Globally On Novel DNA-Damaging Agent With Anticancer Properties

DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR(r) artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties. These patent applications include claims directed to a newly synthesized compound with promising in-vitro anticancer activity in a range of indications that are distinct from LP-184. This compound, newly designated as LP-284, is believed to act through mechanisms that are related to DNA-damage and DNA-repair inhibition in certain cancer cells.